Why NIH is shrinking the number of research grants it funds

The National Cancer Institute informed scientists last week that it expected to be able to fund just 4% of grant applications, down from 9%.

July 29, 2025 Check out STAT+

Sponsored By

Win McNamee/Getty Images STAT+ | NIH is shrinking the number of research projects it funds due to a new Trump policy Going forward, NIH will shift from spreading out the cost of grants over five years to fully funding them up-front, when they're awarded By Angus Chen, Megan Molteni, and Anil Oza Major Alzheimer's group says some blood tests may be used in place of brain scans for diagnosis Alzheimer's Association now recommends certain blood tests for diagnosing the condition, a shift that could expand access to treatment. By Elaine Chen STAT+ | Preventive care panel could be restructured 'imminently' as RFK Jr. vets new members RFK Jr. is vetting new members for a key federal health panel, and one ally says he's likely to pick people who align more closely with his goals. By Chelsea Cirruzzo PATRICK T. FALLON/AFP via Getty Images Opinion: I'm a neurologist. My brother has schizophrenia. I support making involuntary commitment easier U.S. needs a legal, medical framework that allows us to treat not just the willing, but the vulnerable, writes neurologist whose brother has schizophrenia. By Shaheen E. Lakhan STAT+ | UnitedHealth CEO says some parts of business need 'fundamental reorientation' Stephen Hemsley, UnitedHealth's returning CEO, said parts of the firm need "fundamental reorientation," as it faces a range of challenges. By Bob Herman and Tara Bannow Trump administration moves to ban concentrated 7-OH, kratom-related synthetic Kratom itself will remain largely unregulated. Supplements containing elevated levels of 7-OH, however, would likely be banned. By Lev Facher and Lizzy Lawrence Science Photo Library STAT+ | Cellular 'trash bins' might be a key to reviving multi-cancer early detection tests Scientists are shifting from DNA-based blood tests to tiny vesicles once dismissed as cellular trash. They may help catch cancer sooner By Angus Chen and Marissa Russo STAT+ | Novo Nordisk names new CEO as it cuts growth outlook The announcement came as Novo cut its 2025 outlook, citing slower growth of its obesity and diabetes drugs and competition from compounders. By Elaine Chen Opinion: How the FDA can score quick wins on transparency Upgrading how the FDA stores public data and documents about already-approved drugs would be a transparency win. By Frank David

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser